Introduction: Insulin as a Multifunctional Mediator in Skin Healing

Insulin is classically known for its role in glucose homeostasis, but its biological influence reaches far beyond the pancreas and metabolism. Within the skin, insulin acts as a potent growth factor that orchestrates cell survival, proliferation, migration, and differentiation across all stages of wound repair. This expanded view is transforming wound management, particularly for patients with diabetes, where impaired insulin signaling is a primary driver of chronic, non-healing ulcers. Understanding the molecular and cellular mechanisms through which insulin governs cutaneous healing allows clinicians to leverage this hormone for therapeutic benefit and to develop targeted strategies for patients with insulin-resistant states.

The Four Phases of Cutaneous Wound Healing

Wound healing proceeds through four overlapping but distinct phases: hemostasis, inflammation, proliferation, and remodeling. Insulin exerts specific, phase-dependent effects by modulating intracellular signaling cascades, growth factor release, and metabolic pathways. Disruption of insulin action at any of these stages can delay healing, while exogenous insulin therapy can accelerate repair in both normal and compromised tissues.

Hemostasis: Insulin and Platelet-Derived Signals

Immediately after injury, vasoconstriction and platelet aggregation produce a fibrin clot that serves as a provisional scaffold. Insulin receptors expressed on platelet membranes enhance degranulation, increasing the local concentration of platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other chemotactic factors. These molecules recruit neutrophils and macrophages to the wound site and prime fibroblasts for subsequent extracellular matrix synthesis. While the hemostatic phase is brief, the signaling events initiated here set the stage for later repair. Insulin's capacity to boost growth factor bioavailability during this early window may partially explain why topical insulin applied shortly after wounding improves overall healing kinetics.

Inflammation: Balancing Immune Responses

The inflammatory phase is essential for clearing debris and pathogens, but uncontrolled inflammation causes collateral tissue damage and stalls healing. Insulin acts as a powerful immunomodulator by suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while elevating anti-inflammatory mediators such as IL-10 and IL-1 receptor antagonist. This shift protects healthy tissue and facilitates the transition to proliferation. Insulin also enhances macrophage phagocytosis and efferocytosis, promoting the clearance of apoptotic neutrophils and reducing necrotic burden. In diabetic wounds, macrophages often remain locked in a pro-inflammatory M1 phenotype; insulin therapy helps drive their polarization toward the pro-repair M2 state, re-establishing a productive healing environment. The hormone additionally modulates neutrophil chemotaxis and oxidative burst, limiting excessive reactive oxygen species production while preserving antimicrobial function.

Proliferation: Driving Cell Growth and Angiogenesis

The proliferative phase is where insulin exerts its most pronounced effects. Activation of the PI3K/Akt pathway in keratinocytes and fibroblasts stimulates proliferation and migration. Insulin upregulates keratins, integrins, and matrix metalloproteinases required for re-epithelialization. Simultaneously, it promotes fibroblast collagen synthesis and deposition of fibronectin and hyaluronic acid. A key action is the upregulation of vascular endothelial growth factor (VEGF) in endothelial cells and macrophages, driving angiogenesis. In preclinical models, topical insulin increased wound closure rates by up to 40%, primarily through enhanced granulation tissue formation and neovascularization. Clinical studies report that insulin-treated wounds exhibit faster epithelialization and greater reduction in wound area compared to standard care. Insulin also mobilizes circulating endothelial progenitor cells to the wound site, further supporting vessel formation and tissue perfusion.

Remodeling: Collagen Organization and Scar Quality

During remodeling, type III collagen is replaced by type I collagen, and the wound gains tensile strength. Insulin promotes fibroblast-to-myofibroblast differentiation, facilitating wound contraction. It also regulates matrix metalloproteinase (MMP) activity, preventing excessive collagen degradation and reducing the risk of hypertrophic scarring. Clinical data show that insulin-treated wounds have improved tensile strength and more favorable scar appearance, with reduced fibrosis in some contexts. Insulin may also downregulate TGF-β1 signaling under certain conditions, balancing contraction with scar minimization. This dual action makes insulin an attractive candidate for improving both functional and cosmetic outcomes.

Molecular Mechanisms: Insulin Signaling in Skin Cells

Insulin binds to the insulin receptor (IR), a transmembrane tyrosine kinase that activates two main intracellular cascades: the PI3K/Akt pathway and the MAPK/ERK pathway. These pathways mediate distinct but overlapping functions that collectively support wound repair.

PI3K/Akt Pathway: Metabolic and Pro-Survival Signals

The PI3K/Akt pathway is the primary mediator of insulin's metabolic and growth-promoting effects. Akt phosphorylates downstream targets including mTOR, which enhances mRNA translation of collagen, elastin, and other matrix proteins. Akt also inactivates pro-apoptotic factors such as Bad and caspase-9, promoting cell survival in the harsh wound environment. In keratinocytes, PI3K/Akt signaling is essential for migration and re-epithelialization; in fibroblasts, it drives proliferation and matrix synthesis. The pathway also facilitates glucose uptake via GLUT4 translocation, providing energy for the high metabolic demands of healing cells. Disruption of PI3K/Akt signaling, as seen in insulin resistance, severely impairs wound healing.

MAPK/ERK Pathway: Proliferation and Angiogenesis

The MAPK/ERK pathway regulates gene expression related to cell cycle progression, differentiation, and angiogenesis. Insulin-induced ERK activation in endothelial cells stimulates VEGF production, driving new blood vessel formation. In keratinocytes, MAPK signaling promotes migration and proliferation, while in fibroblasts it contributes to matrix synthesis. The pathway also cross-talks with inflammatory signaling, helping coordinate the transition from inflammation to proliferation. Selective inhibition of MAPK signaling in preclinical models delays wound closure and reduces angiogenesis, underscoring its importance in insulin-mediated repair.

Insulin and IGF-1 Receptor Cross-Talk

Insulin also activates the insulin-like growth factor-1 (IGF-1) receptor, which shares high structural homology with the insulin receptor. Both receptors can form hybrid complexes with varying affinities for insulin and IGF-1. Together, they amplify anabolic signals in wound tissue, promoting cell growth and survival. This redundancy explains why insulin resistance profoundly impairs healing: when insulin signaling is blunted, the compensatory capacity of the IGF-1 system is often insufficient to maintain normal repair kinetics. Understanding this cross-talk is important for developing therapies that bypass or restore defective signaling in chronic wounds.

Insulin Resistance at the Cellular Level

In insulin-resistant states, post-receptor signaling is impaired through mechanisms such as serine phosphorylation of IRS-1, reduced PI3K activation, and increased phosphatase activity. Hyperglycemia further exacerbates resistance by inducing oxidative stress and advanced glycation end-products (AGEs) that interfere with receptor function. The net result is reduced Akt and ERK activation, leading to decreased cell proliferation, migration, and angiogenesis. Topical insulin can partially overcome local resistance by providing supraphysiological concentrations that saturate remaining receptors and activate alternative pathways.

Clinical Implications: Insulin Resistance and Chronic Wounds

In patients with type 2 diabetes, insulin resistance impairs the hormone's ability to drive healing processes. Hyperglycemia further damages microvasculature and peripheral nerves, creating a permissive environment for chronic wound development. Diabetic foot ulcers (DFUs) affect approximately 15% of diabetic patients and precede the majority of non-traumatic lower extremity amputations. The combination of defective insulin signaling, elevated glucose, and oxidative stress creates a vicious cycle of persistent inflammation, impaired angiogenesis, and increased infection risk.

Why Diabetic Wounds Heal Slowly

  • Reduced growth factor response: Keratinocytes and fibroblasts become less sensitive to insulin and IGF-1, diminishing proliferative and migratory capacity.
  • Impaired angiogenesis: VEGF levels are low, and capillary density is reduced, limiting oxygen and nutrient delivery.
  • Dysregulated inflammation: Macrophages fail to transition from pro-inflammatory M1 to pro-repair M2 phenotype, perpetuating tissue damage.
  • Increased infection risk: Hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and bacterial killing.
  • Extracellular matrix abnormalities: AGEs cross-link collagen, reducing matrix turnover and elasticity.

Restoring insulin sensitivity is a primary therapeutic goal. Intensive glycemic control, as demonstrated in the Diabetes Control and Complications Trial (DCCT), correlates with a 35% reduction in wound healing complications (DCCT Research Group). However, even with tight glucose management, many patients develop chronic wounds, prompting research into direct insulin applications that bypass systemic resistance.

Therapeutic Uses of Insulin in Wound Care: Topical and Systemic Strategies

Beyond glycemic control, insulin is increasingly explored as a topical agent. Several clinical trials have examined insulin-soaked dressings, gels, and scaffolds for DFUs, pressure ulcers, venous leg ulcers, and surgical wounds.

Topical Insulin Application

Topical insulin typically involves applying regular insulin (10–20 units per dressing) directly to the wound bed once or twice daily. A meta-analysis of 14 randomized controlled trials involving over 800 patients found that topical insulin significantly reduced time to complete wound closure by an average of 8.2 days compared to standard care (Wang et al., 2019). Benefits include accelerated granulation tissue formation, earlier epithelialization, and greater reduction in wound area. The effect is most pronounced in chronic wounds that have failed conventional therapy, suggesting topical insulin is valuable as a second-line or adjunctive treatment.

Mechanisms of Topical Insulin Action

Local application delivers high insulin concentrations directly to the wound bed, bypassing systemic resistance. It activates local insulin receptors, increases VEGF and collagen synthesis, and enhances recruitment of bone marrow-derived stem cells. Topical insulin also appears to improve nerve regeneration and sensory recovery in diabetic feet, addressing both healing and neuropathic deficits. Some evidence suggests direct antimicrobial effects by modulating local immune responses and reducing bacterial colonization, though this area requires further study.

Safety and Dosing Considerations

Topical insulin rarely causes systemic hypoglycemia due to limited absorption through intact skin and wound tissue. However, caution is advised for large wounds, in patients with labile glucose levels, or when used with systemic insulin. Some trials report transient local irritation, mild burning, or hypergranulation, but serious adverse events are uncommon. Current international guidelines do not yet include topical insulin as routine, but accumulating evidence supports its use in selected patients under supervision. Dosing regimens vary; research continues to define optimal concentration, frequency, and duration.

Advanced Formulations and Delivery Systems

Researchers are developing advanced formulations to optimize topical insulin delivery and prolong local activity. Hydrogels, nano-carriers, and electrospun scaffolds can encapsulate insulin for sustained release, reducing dressing change frequency and improving compliance. Preclinical data indicate that a single application of insulin-loaded hydrogel maintains therapeutic levels for up to 72 hours, with corresponding improvements in wound closure and angiogenesis. Combining insulin with other growth factors such as PDGF, EGF, or FGF may offer synergistic benefits, especially in wounds with multiple healing deficits.

Personalized and Responsive Approaches

Emerging strategies aim to tailor insulin therapy based on individual wound characteristics. Wound pH, protease activity, and bacterial load influence insulin stability and efficacy. Smart delivery systems that release insulin in response to specific wound microenvironments (e.g., elevated MMP activity or pH) are in early development. Personalized dosing algorithms accounting for wound size, depth, and healing trajectory may further improve outcomes. Integrating insulin therapy with advanced wound dressings, negative pressure wound therapy, or skin substitutes represents a logical next step for clinical research.

Future Directions and Unanswered Questions

Despite promising data, several questions remain. Optimal dosing regimens, treatment duration, and patient selection criteria have not been standardized. Long-term safety data, especially regarding carcinogenicity or effects on pre-existing malignancies, are limited. The role of insulin in combination with other advanced therapies requires investigation. Large-scale, multi-center trials with standardized protocols and long-term follow-up are needed to establish definitive clinical guidelines. Additionally, understanding how insulin resistance develops locally in wounded tissue could lead to targeted therapies that restore insulin sensitivity itself.

Another promising avenue is the use of insulin analogs or mimetics that selectively activate anabolic pathways while minimizing metabolic side effects. For example, IGF-1 analogs or small-molecule activators of the insulin receptor could provide more targeted repair signals. Finally, research into the circadian regulation of insulin sensitivity in skin may reveal optimal timing for insulin application to maximize healing outcomes.

Conclusion

Insulin is far more than a glucose-regulating hormone. It is a pleiotropic mediator of skin repair that influences hemostasis, inflammation, proliferation, and remodeling through direct cellular signaling and growth factor modulation. For clinicians, recognizing the impact of insulin resistance on wound outcomes is essential for effective diabetes management and wound care. Topical insulin offers a promising, low-cost adjunctive therapy for chronic wounds, with a growing evidence base supporting its safety and efficacy. Continued research into advanced formulations, combination therapies, and personalized delivery systems will expand the role of insulin in wound management, particularly for the growing population of patients with diabetes and impaired healing capacity.

To stay informed on the latest evidence, consult resources such as the American Diabetes Association Clinical Diabetes Journal, the NIH Wound Healing Guidelines, and recent reviews on insulin signaling in wound repair (Oryan et al., 2020).